Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05824585
PHASE1

DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Sponsor: Dizal Pharmaceuticals

View on ClinicalTrials.gov

Summary

This study will treat patients with B-NHL who have relapsed, progressed, or were intolerant to systemic therapy progressed following prior therapy. This study will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and assess its anti-cancer activity as monotherapy.

Official title: A Phase 1, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

230

Start Date

2023-05-15

Completion Date

2027-10-30

Last Updated

2025-08-11

Healthy Volunteers

No

Interventions

DRUG

DZD8586

DZD8586 treatment starting from 50 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD8586.

Locations (5)

Research site

New York, New York, United States

Research site

Albury, New South Wales, Australia

Research site

Ballarat, Victoria, Australia

Research site

Melbourne, Victoria, Australia

Research site

Perth, Western Australia, Australia